Boehringer Ingelheim takes Evotec’s painkiller into clinic
Hamburg/Ingelheim: Evotec AG’s second oral compound against neuropathic pain has reached clinical development stage. The progress triggered a EUR 2 million milestone from Boehringer Ingelheim that will pay all clinical development and commercialisation costs of compounds co-developed within the ongoing strategic alliance the companies initially signed in 2004. Neuropathic pain, which is estimated to affect up to 8% of the world’s population, is a type of pain caused by damage to or dysfunction of the nervous system. This March, Boehringer Ingelheim prematurately terminated a first-in-man dose escalation study (NCT01145014) of its compound BI 660848, intended to be developed in neuropathic pain, due to „new embryotoxicology data but not for safety reasons“. The transition of the new back-up compound into clinical stage triggered the 13th milestone for Evotec within the alliance with Boehringer Ingelheim that includes several unnamed compounds „working on multiple high priority targets across key therapeutic areas“. Following the end of the collaboration with Roche on EVT 101, Evotec which increased its Q1/2011 revenues by more than 50% (EUR15.1m) compared to Q1/2010, requires a positive newsflow.